{
    "nctId": "NCT01788839",
    "briefTitle": "Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma",
    "officialTitle": "Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Lymphoma, Hodgkin's Lymphoma",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 400,
    "primaryOutcomeMeasure": "determine the natural history of sexual and reproductive health",
    "eligibilityCriteria": "Inclusion Criteria:\n\nSubject Inclusion Criteria for Cohort of Premenopausal Women with Early Stage Breast Cancer and Lymphoma\n\n* Women, 18 years of age and older\n* Premenopausal women at time of diagnosis who have either been pregnant or had at least one menstrual period in the last 12 months\n\n  * Note: premenopausal women at time of diagnosis who have not been pregnant or have not had at least one menstrual period in the last 12 months are able to participate only if they have had an intrauterine device (IUD) in place within the last 12 months.\n* Women with newly diagnosed breast cancer (stage 0-III) who are within 1 month of starting systemic treatment or women with any aggressive lymphoma being treated with first line therapy with curative intent.\n* Breast cancer patients with any receptor type\n* English speaking\n* Able to participate in the informed consent process\n\nSubject Inclusion Criteria for Tamoxifen Only Subset of Cohort of Premenopausal Women with Early Stage Breast Cancer and Lymphoma\n\n* Women, 18 years of age and older.\n* Premenopausal women at time of diagnosis who have either been pregnant or had at least one menstrual period in the last 12 months\n\n  * Note: premenopausal women at time of diagnosis who have not been pregnant or have not had at least one menstrual period in the last 12 months are able to participate only if they have had an intrauterine device (IUD) in place within the last 12 months.\n* Women with newly diagnosed breast cancer (stage 0-III) who have not yet started treatment and are planning to start Tamoxifen as their only form of systemic treatment within one month\n* Breast cancer patients with any receptor type\n* English speaking\n* Able to participate in the informed consent process\n\nSubject Inclusion Criteria for Cohort of Postmenopausal Women with Early Stage Breast Cancer and Lymphoma\n\n* Women, 18 years of age and older.\n* Postmenopausal women at time of diagnosis who have been without period for \u2265 2 years.\n* Women with newly diagnosed breast cancer (stage 0-III) who are within 1 month of starting systemic treatment or women with any aggressive lymphoma being treated with first line therapy with curative intent.\n* Breast cancer patients with any receptor type\n* English speaking\n* Able to participate in the informed consent process\n\nExclusion Criteria:\n\nSubject Exclusion Criteria for both Pre and Postmenopausal Women with Early Stage Breast Cancer and Lymphoma\n\n* Active secondary cancer requiring cytotoxic chemotherapy\n* Prior systemic treatment for a malignancy",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}